This trial is testing daratumumab, hyaluronidase-fihj, and pomalidomide to see if they work well together to treat patients with relapsed multiple myeloma.
2 Primary · 0 Secondary · Reporting Duration: From the date of initiation of maintenance therapy assessed up to 2 years
Experimental Treatment
56 Total Participants · 1 Treatment Group
Primary Treatment: Daratumumab · No Placebo Group · Phase 2
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: